Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions
A Look at What Drug Manufacturers are Likely Using to Make CAR-T Products
Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
For full access to this article login to GEN Select now.
Introducing In Vitro ADMET Studies Earlier
Researchers Are Generating Novel Assays to Cover All Areas of Selection and Safety Testing
- Drug discovery and development is a high-cost/high-risk endeavor. On average, the process to bring a candidate from conception to market takes 12–15 years and costs, at current estimates, $1.8 billion. Whether or not a drug is a blockbuster, late-stage attrition due to on- or off-target toxicity can be devastating for ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.